MeiraGTx posts corporate deck highlighting late-stage gene therapy pipeline, riboswitch platform
Reuters2026/08/13 12:23- MeiraGTx highlighted four late-stage gene therapy programs, led by AAV-AQP1 in pivotal Phase 2 for radiation-induced xerostomia.
- BLA filing for AAV-AQP1 targeted for mid 2027, supported by Breakthrough Therapy, RMAT, orphan drug designations.
- Botaretigene sparoparvovec in X-linked retinitis pigmentosa completed Phase 3; BLA and MAA submissions planned in 2026.
- AAV-GAD in Parkinson’s disease described as Phase 3 ready; potential BLA filing targeted in 2028.
- Partnership updates included Eli Lilly paying USD 75 million upfront for AAV-AIPL1, with up to USD 135 million near-term milestones.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
Crypto prices
More
